NCT01567085View on ClinicalTrials.gov

Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 29, 2012

Primary Completion Date

June 11, 2015

Study Completion Date

May 24, 2017

Conditions
Stage V Chronic Kidney Disease
Interventions
DRUG

Eculizumab

Trial Locations (15)

2050

Camperdown

3050

Parkville

5000

Adelaide

25123

Brescia

31059

Toulouse

33076

Bordeaux

35128

Padua

37044

Tours

75010

Paris

75743

Paris

08907

Barcelona

413 45

Gothenburg

751 85

Uppsala

CB2 2QQ

Cambridge

SE1 9RT

London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY